On May 12, at the European Medicines Verification Organisation’s (EMVO) General Assembly meeting, the NMVO Observers within EMVO’s Board for 2023 from the National Medicines Verification Organizations (NMVOs) were approved. As one of the observers representing the group of small-scale countries (Slovakia, Norway, Croatia, Cyprus, Estonia, Iceland, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta and Slovenia), will be the Latvian Medicines Verification Organisation (LZVO) and its Chairwoman of the Board Inese Erdmane.
The Polish Medicines Verification Organisation (KOWAL) and its General Manager Iwona McManus, representing the group of large-scale countries, as well as the Swedish Medicines Verification Organisation (e-VIS) and its General Manager Kristina von Sydow, representing the group of medium-scale countries, will work together with LZVO as NMVO Observers within EMVO’s Board.
"I am grateful to all our colleagues from the National Medicines Verification Organisations for the trust they have shown me and the opportunity to represent the group of small-scale countries. Being an Observer within EMVO’s Board allows not only to better understand the decision-making processes in the organisation, but also to provide our proposals for the efficient use of the budget in order to further optimize EMVO services for both NMVOs’ and manufacturers' representatives, as well as to ensure stable, safe and reliable operation of the common European Medicines Verification System (EMVS)," explains Inese Erdmane, Chairwoman of the LZVO Board.
Observers within the EMVO’s Board are elected for one year, the nomination and election of candidates is being entrusted to the representatives of the National Medicine Verification Organisations. LZVO will act as an Observer within EMVO Board for the first time.